98 related articles for article (PubMed ID: 1469654)
1. Targeted delivery of human recombinant superoxide dismutase by chemical modification with mono- and polysaccharide derivatives.
Fujita T; Nishikawa M; Tamaki C; Takakura Y; Hashida M; Sezaki H
J Pharmacol Exp Ther; 1992 Dec; 263(3):971-8. PubMed ID: 1469654
[TBL] [Abstract][Full Text] [Related]
2. Targeted delivery and improved therapeutic potential of catalase by chemical modification: combination with superoxide dismutase derivatives.
Yabe Y; Nishikawa M; Tamada A; Takakura Y; Hashida M
J Pharmacol Exp Ther; 1999 May; 289(2):1176-84. PubMed ID: 10215702
[TBL] [Abstract][Full Text] [Related]
3. Manipulation of renal disposition of human recombinant superoxide dismutase by chemical modification.
Mihara K; Sawai K; Takakura Y; Hashida M
Biol Pharm Bull; 1994 Feb; 17(2):296-301. PubMed ID: 7515745
[TBL] [Abstract][Full Text] [Related]
4. Improvement of therapeutic effect of human recombinant superoxide dismutase on ischemic acute renal failure in the rat via cationization and conjugation with polyethylene glycol.
Mihara K; Oka Y; Sawai K; Takakura Y; Hashida M
J Drug Target; 1994; 2(4):317-21. PubMed ID: 7858957
[TBL] [Abstract][Full Text] [Related]
5. Preventive effects of superoxide dismutase derivatives modified with monosaccharides on reperfusion injury in rat liver transplantation.
Mizoe A; Kondo S; Azuma T; Fujioka H; Tanaka K; Hashida M; Kanematsu T
J Surg Res; 1997 Dec; 73(2):160-5. PubMed ID: 9441811
[TBL] [Abstract][Full Text] [Related]
6. Pharmacological advantages of conjugation of Cu, Zn-superoxide dismutase with succinylated keratin fragment: improvement of biological properties and resistance to oxidative damage.
Noda J; Otagiri M; Akaike T; Maeda H
J Pharmacol Exp Ther; 1996 Oct; 279(1):162-71. PubMed ID: 8858989
[TBL] [Abstract][Full Text] [Related]
7. Pharmacokinetic analysis of in vivo disposition of heparin-superoxide dismutase.
Liu J; Zhao T; Tan H; Cheng Y; Cao J; Wang F
Biomed Pharmacother; 2010 Dec; 64(10):686-91. PubMed ID: 20970950
[TBL] [Abstract][Full Text] [Related]
8. Poly(vinylpyrrolidone-co-dimethyl maleic acid) as a novel renal targeting carrier.
Yamamoto Y; Tsutsumi Y; Yoshioka Y; Kamada H; Sato-Kamada K; Okamoto T; Mukai Y; Shibata H; Nakagawa S; Mayumi T
J Control Release; 2004 Mar; 95(2):229-37. PubMed ID: 14980771
[TBL] [Abstract][Full Text] [Related]
9. Plasma clearance of human extracellular-superoxide dismutase C in rabbits.
Karlsson K; Marklund SL
J Clin Invest; 1988 Sep; 82(3):762-6. PubMed ID: 3417870
[TBL] [Abstract][Full Text] [Related]
10. Difference between kidney and liver in decreased manganese superoxide dismutase activity caused by exposure of mice to mercuric chloride.
Shimojo N; Kumagai Y; Nagafune J
Arch Toxicol; 2002 Jul; 76(7):383-7. PubMed ID: 12111001
[TBL] [Abstract][Full Text] [Related]
11. In vivo uptake of Cu, Zn superoxide dismutase. Morphological evidence for preferential endocytosis and accumulation by sinusoidal liver cells.
Dini L; Falasca L; Rossi L; Rotilio G
Cell Mol Biol (Noisy-le-grand); 1996 Mar; 42(2):269-77. PubMed ID: 8696264
[TBL] [Abstract][Full Text] [Related]
12. Disposition characteristics of recombinant human interleukin-11 after a bolus intravenous administration in mice.
Takagi A; Masuda H; Takakura Y; Hashida M
J Pharmacol Exp Ther; 1995 Nov; 275(2):537-43. PubMed ID: 7473136
[TBL] [Abstract][Full Text] [Related]
13. Inhibitory effects of safe and novel SOD derivatives, galactosylated-SOD, on hepatic warm ischemia/reperfusion injury in pigs.
Yuzawa H; Fujioka H; Mizoe A; Azuma T; Furui J; Nishikawa M; Hashida M; Kanematsu T
Hepatogastroenterology; 2005; 52(63):839-43. PubMed ID: 15966216
[TBL] [Abstract][Full Text] [Related]
14. Therapeutic effects of superoxide dismutase derivatives modified with mono- or polysaccharides on hepatic injury induced by ischemia/reperfusion.
Fujita T; Furitsu H; Nishikawa M; Takakura Y; Sezaki H; Hashida M
Biochem Biophys Res Commun; 1992 Nov; 189(1):191-6. PubMed ID: 1449473
[TBL] [Abstract][Full Text] [Related]
15. Mannosylated superoxide dismutase inhibits hepatic reperfusion injury in rats.
Kondo S; Segawa T; Tanaka K; Izawa K; Hashida M; Kanematsu T
J Surg Res; 1996 Jan; 60(1):36-40. PubMed ID: 8592429
[TBL] [Abstract][Full Text] [Related]
16. Pharmacokinetics and safety of intravenous recombinant human superoxide dismutase (NK341) in healthy subjects.
Uematsu T; Nagashima S; Umemura K; Kanamaru M; Nakashima M
Int J Clin Pharmacol Ther; 1994 Dec; 32(12):638-41. PubMed ID: 7881700
[TBL] [Abstract][Full Text] [Related]
17. Prevention of neutrophil-mediated hepatic ischemia/reperfusion injury by superoxide dismutase and catalase derivatives.
Yabe Y; Kobayashi N; Nishihashi T; Takahashi R; Nishikawa M; Takakura Y; Hashida M
J Pharmacol Exp Ther; 2001 Sep; 298(3):894-9. PubMed ID: 11504782
[TBL] [Abstract][Full Text] [Related]
18. Disposition characteristics of glycosylated poly(amino acids) as liver cell-specific drug carrier.
Akamatsu K; Imai M; Yamasaki Y; Nishikawa M; Takakura Y; Hashida M
J Drug Target; 1998; 6(3):229-39. PubMed ID: 9888309
[TBL] [Abstract][Full Text] [Related]
19. Turnover of extracellular-superoxide dismutase in tissues.
Karlsson K; Sandström J; Edlund A; Marklund SL
Lab Invest; 1994 May; 70(5):705-10. PubMed ID: 8196366
[TBL] [Abstract][Full Text] [Related]
20. Lecithinization of superoxide dismutase potentiates its protective effect against Forssman antiserum-induced elevation in guinea pig airway resistance.
Igarashi R; Hoshino J; Takenaga M; Kawai S; Morizawa Y; Yasuda A; Otani M; Mizushima Y
J Pharmacol Exp Ther; 1992 Sep; 262(3):1214-9. PubMed ID: 1527725
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
